Dynamic balancing of the dual nature of HIF-1α for cell survival

Cell Cycle

Volumn 3, Issue 7, 2004, Pages 853-854

  Koshiji, Minori ^a   Huang, L Eric ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell cycle; Drug resistance; HIF 1 ; Hypoxia; Myc; p21cip1

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYC PROTEIN; OXYGEN;

ANGIOGENESIS; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL SURVIVAL; DNA RESPONSIVE ELEMENT; GENE; GLYCOLYSIS; GROWTH INHIBITION; HYPOXIA RESPONSIVE ELEMENT; P21 CIP1 GENE; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DNA INTERACTION; REVIEW; TRANSCRIPTION INITIATION; TUMOR CELL;

EID: 13144275217     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. 2- regulated gene expression. FASEB J 2002; 16:1151-62.
2. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8:S62-7.
3. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003; 13:83-9.
4. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003; 278:19575-8.
5. 2 tension. Proc Natl Acad Sci USA 1995; 92:5510-4.
6. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996; 271:32253-9.
7. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95:7987-92.
8. Kallio PJ, Wilson WJ, O'Brien S, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999; 274:6519-25.
9. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatoty domains within the alpha subunit. J Biol Chem 1997; 272:11205-14.
10. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230-7.
11. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 1996; 93:12969-73.
12. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α. EMBO J 1998; 17: 6573-86.
13. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-90.
14. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23:359-69.
15. Salnikow K, Costa M, Figg WD, Blagosklonny MV. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res 2000; 60:5630-4.
16. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23:1949-56.
17. Herold S, Wanzel M, Beuger V, Frohme C, Beul D, Hillukkala T, et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 2002; 10:509-21.
18. Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419:729-34.
19. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003; 283:17-21.
20. Harris AL. Hypoxia-a key regulatoty factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
21. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53:1192-202.
22. WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res 2002; 6:193-202.